株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国の血液製剤産業

China Blood Product Industry Report, 2017-2021

発行 ResearchInChina 商品コード 210301
出版日 ページ情報 英文 125 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.34円で換算しております。
Back to Top
中国の血液製剤産業 China Blood Product Industry Report, 2017-2021
出版日: 2017年04月25日 ページ情報: 英文 125 Pages
概要

当レポートでは、中国の血液製剤産業について調査分析し、産業の概要、中国市場の動向、製品セグメント別の分析、主要企業、発展予測などについて、体系的な情報を提供しています。

第1章 血液製剤産業の概要

  • 定義
  • 分類
  • 組み換え血液製剤
  • 産業チェーン
  • 特徴

第2章 中国の血液製剤産業の発展

  • 現状
  • 政策環境
  • 需要と供給
  • 市場規模
  • 市場構造
  • 競合パターン

第3章 中国の血液製剤産業セグメント

  • ヒトアルブミン
  • 静脈注射用ヒト免疫グロブリン (pH4)
  • 血液凝固第VII因子
  • B型肝炎免疫グロブリン
  • ヒト免疫グロブリン
  • ヒトプロトロンビン複合体
  • 破傷風免疫グロブリン
  • 狂犬病免疫グロブリン

第4章 中国の主要メーカー

第5章 サマリーと予測

  • サマリーと予測
  • 動向

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: ZLC048

China's blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 2015, estimated to reach RMB23.8 billion throughout the year, up 16.7% from 2015.

China's blood product industry will develop at full speed boosted by downstream demand, accompanied by a steady rise in the number of plasma stations and consolidated profit margin improvement of plasma. The market size is expected to hit RMB47.5 billion in 2021.

Main features of blood product industry in China 2016 are shown as below:

1. As plasma supply increases, supply-demand balance can be seen in 2025

  • China's plasma collection volume has been increasing over recent years driven by blood product price deregulation and accelerated establishment of new plasma stations. In 2016, 6,964 tons of plasma was collected in China, up 19.8% year on year. Despite continuous growth, plasma collection volume still cannot meet the ever-increasing market demand. In the future, China will see plasma collection volume shooting up propelled by a growing number of plasma collection stations and is expected to achieve balance between plasma supply and demand in 2025.

2. A steady increase in lot release volume of main products

  • So far, Chinese blood products are still dominated by human albumin and human immunoglobulin for intravenous injection, which take an over 70% blood product market share. In 2016, human albumin and human immunoglobulin (pH4) for intravenous injection registered respective lot release volumes of 39.31 million bottles (10g/bottle) and 10.89 million bottles (2.5g/bottle), up 17.8% and 27.4% respectively year on year.

In addition, lot release volumes of domestic blood products in short supply such as blood coagulation factor VIII, human immunoglobulin and human prothrombin complex also witnessed substantial growth in 2016, respectively 38.0%, 143.8% and 20%.

3. R&D efforts intensified for new products; comprehensive utilization of plasma to be raised

  • At present, Chinese blood product enterprises can separate a maximum of 11 varieties of blood products from the plasma, 3-4 varieties for general firms, indicating an extremely low rate of comprehensive utilization of plasmas. To solve the problem, Chinese blood product enterprises are accelerating the development of new products, hoping to improve comprehensive utilization of plasma.

Blood coagulation factor VIII, for example, Guizhou Taibang Biological Products Co., Ltd., Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Zhenxing Biopharmaceutical & Chemical Co., Ltd., Wuhan Zhongyuan Ruide Biological Products Co., Ltd. etc. are actively conducting clinical trials of blood coagulation factor VIII and expected to achieve mass production in next two years.

4 Plasma-oriented pattern continues

  • Blood product industry relies heavily on plasma materials - the number of plasma stations directly influences plasma collection volume, which then affects raw material supply of blood product enterprises. Therefore, the number of plasma stations and plasma collection volume determine corporate position in industry.

There are over 30 blood product manufacturing enterprises in China, but only more than 20 are able to maintain normal production. Among them, Hualan Biological Engineering,Inc., Shanghai RAAS Blood Products Co., Ltd. and China Biologic Products, Inc. boast relatively high volume of plasma collection, altogether accounting for 39.6% of total plasma collections in 2016.

image1

The report highlights the following:

  • Analysis on development of China blood product industry, including status quo, policy environment, market supply & demand, market size, market structure and competition pattern;
  • Analysis on 8 market segments of China blood product industry, including development status, competition pattern and trends;
  • Analysis on 13 major enterprises, including operation, blood product business, etc.; Summary & forecast and trends.

Table of Contents

1 Overview of Blood Products

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Recombinant Blood Products
  • 1.4 Industry Chain
  • 1.5 Features

2 Development of China Blood Product Industry

  • 2.1 Status Quo
  • 2.2 Policy Environment
  • 2.3 Market Supply and Demand
    • 2.3.1 Supply
    • 2.3.2 Demand
  • 2.4 Market Size
  • 2.5 Market Structure
  • 2.6 Competition Pattern

3 Market Segments of China Blood Product Industry

  • 3.1 Human Albumin
    • 3.1.1 Development Status
    • 3.1.2 Competition Pattern
    • 3.1.3 Prospects
  • 3.2 Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1 Development Status
    • 3.2.2 Competition Pattern
    • 3.2.3 Prospects
  • 3.3 Blood Coagulation Factor VIII
    • 3.3.1 Development Status
    • 3.3.2 Competition Pattern
    • 3.3.3 Prospects
  • 3.4 Hepatitis B Immunoglobulin
    • 3.4.1 Development Status
    • 3.4.2 Competition Pattern
  • 3.5 Human Immunoglobulin
    • 3.5.1 Development Status
    • 3.5.2 Competition Pattern
  • 3.6 Human Prothrombin Complex
    • 3.6.1 Development Status
    • 3.6.2 Competition Pattern
  • 3.7 Tetanus Immunoglobulin
    • 3.7.1 Development Status
    • 3.7.2 Competition Pattern
  • 3.8 Human Rabies Immunoglobulin
    • 3.8.1 Development Status
    • 3.8.2 Competition Pattern

4 Major Enterprises

  • 4.1 China Biologic Products, Inc. (NASDAQ: CBPO)
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 R&D and Investment
    • 4.1.6 Shandong Taibang Biological Products Co., Ltd.
    • 4.1.7 Guizhou Taibang Biological Products Co., Ltd.
    • 4.1.8 Xi'an Huitian Blood Products Co., Ltd.
    • 4.1.9 Development and Forecast
  • 4.2 Hualan Biological Engineering,Inc.
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D and Investment
    • 4.2.6 Customer
    • 4.2.7 Blood Product Business
    • 4.2.8 Development and Forecast
  • 4.3 Shanghai RAAS Blood Products Co., Ltd.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D and Investment
    • 4.3.6 Customer
    • 4.3.7 Blood Product Business
    • 4.3.8 Development and Forecast
  • 4.4 Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO)
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D and Investment
    • 4.4.6 Customer
    • 4.4.7 Blood Product Business
    • 4.4.8 Development and Forecast
  • 4.5 Zhenxing Biopharmaceutical & Chemical Co., Ltd.
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 Customer
    • 4.5.6 R&D and Investment
    • 4.5.7 Blood Product Business
    • 4.5.8 Development and Forecast
  • 4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D and Investment
    • 4.6.6 Customer
    • 4.6.7 Blood Product Business
    • 4.6.8 Development and Forecast
  • 4.7 Humanwell Healthcare Group Co., Ltd.
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D and Investment
    • 4.7.6 Blood Product Business
    • 4.7.7 Development and Forecast
  • 4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Blood Product Business
  • 4.9 Shanghai Institute of Biological Products Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Blood Product Business
  • 4.10 Shanxi Kangbao Biological Product Co., Ltd.
    • 4.10.1 Profile
    • 4.10.2 Blood Product Business
  • 4.11 Green Cross China
    • 4.11.1 Profile
    • 4.11.2 Blood Product Business
  • 4.12 Walvax Biotechnology Co, Ltd.
    • 4.12.1 Profile
    • 4.12.2 Operation
    • 4.12.3 Blood Product Business
  • 4.13 Shenzhen Weiguang Biological Products Co., Ltd.
    • 4.13.1 Profile
    • 4.13.2 Operation
    • 4.13.3 Revenue Structure
    • 4.13.4 Gross Margin
    • 4.13.5 Customer
    • 4.13.6 R&D and Investment
    • 4.13.7 Blood Product Business

5 Summary and Forecast

  • 5.1 Summary and Forecast
  • 5.2 Trends
    • 5.2.1 Policies Encourage Industrial Development
    • 5.2.2 Industrial Consolidation Accelerates, Concentration Further Enhances
    • 5.2.3 Demand-Supply Gap and Product Consumption Structure Improvement are Beneficial to Industrial Development
    • 5.2.4 Plasma Collection Volume and Number of Plasma Stations Determine Position in Industry
    • 5.2.5 Comprehensive Utilization of Plasma Increases

Selected Charts

  • Basic Components of Blood
  • Separation Procedure of Plasma Proteins
  • Classification and Function of Blood Products
  • Comparison of Gene Recombinant Blood Products and Traditional Blood Products
  • Types and Comparison of Domestic and Foreign Blood Products
  • Blood Product Industry Chain
  • Time Consumption of Plasma Collection and Separation Process
  • Comparison of Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
  • Production & Sales Cycle of Blood Products
  • Development History of China Blood Product Industry
  • Lot Release Volume of Major Blood Products in China, 2014-2016
  • Main Policies on China Blood Product Industry, 1989-2016
  • Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Occident
  • Plasma Collection in China vs. USA
  • Public Acceptance of Plasma Donation in China vs. USA, 2015
  • Plasma Collection Volume and YoY Growth Rate in China, 2008-2016
  • Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2016
  • Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2016
  • Plasma Supply and Demand in China, 2015-2025E
  • Blood Product Price Changes in China
  • Market Size of China Blood Product Industry, 2010-2016
  • Blood Product Structure in China (by Lot Release Volume), 2014-2016
  • Number of Plasma Stations and Production-use Plasma Volume of Major Blood Product Enterprises in China, 2016
  • Main Products of Major Blood Product Manufacturing Enterprises in China
  • Revenue of Major Blood Product Enterprises in China, 2013-2016
  • Net Income of Major Blood Product Enterprises in China, 2013-2016
  • R&D Expenditures of Major Blood Product Enterprises in China, 2013-2016
  • Comparison of Blood Product Revenue between Major Blood Product Enterprises in China, 2013-2016
  • Market Share of China Blood Product Industry (by Enterprise), 2016
  • Market Share of China Blood Product Industry (by Enterprise), 2015
  • Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2016
  • Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2016
  • Market Share of Human Albumin in China (by Lot Release Volume), 2016
  • Human Albumin Sales of Major Human Albumin Enterprises in China, 2013-2016
  • Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2016
  • Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2016
  • Human Immunoglobulin (pH4) for Intravenous Injection Sales of Major Human Immunoglobulin (pH4) for Intravenous Injection Enterprises in China, 2013-2016
  • Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2016
  • Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2016
  • Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2016
  • Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2016
  • Lot Release Volume of Human Immunoglobulin in China, 2010-2016
  • Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2016
  • Lot Release Volume of Human Prothrombin Complex in China, 2010-2016
  • Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2016
  • Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2016
  • Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2016
  • Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2016
  • Lot Release Volume of Rabies Vaccine in China, 2010-2016
  • Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2016
  • Product Line of CBPO
  • Ownership Structure of CBPO, 2016
  • Revenue and Operating Income of CBPO, 2011-2016
  • Lot Release Volume of Blood Products of CBPO, 2015-2016
  • Revenue Breakdown of CBPO (by Product), 2011-2016
  • Revenue Structure of CBPO (by Product), 2011-2016
  • Market Share of CBPO (by Product), 2016
  • Gross Margin of CBPO, 2011-2016
  • R&D Costs and % of Total Revenue of CBPO, 2011-2016
  • CBPO's Products under Research and R&D Process by the end of 2016
  • Ownership Structure of Shandong Taibang Biological Products
  • Main Plasma Collection Stations of Shandong Taibang Biological Products as of Mar 2017
  • Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Mar 2017
  • Ownership Structure of Xi'an Huitian Blood Products
  • Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2014
  • Main Plasma Collection Stations of Xi'an Huitian Blood Products as of Mar 2017
  • Revenue and Net Income of CBPO, 2016-2021E
  • Revenue and Net Income of Hualan Biological Engineering, 2013-2016
  • Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2016
  • Revenue Structure of Hualan Biological Engineering (by Product), 2013-2016
  • Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2016
  • R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2016
  • Hualan Biological Engineering's Sales from Top 5 Customers and % of Total Sales, 2013-2016
  • Category and Specification of Blood Products of Hualan Biological Engineering
  • Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2013-2016
  • Revenue of Blood Products of Hualan Biological Engineering, 2013-2016
  • Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2016
  • Revenue and Net Income of Hualan Biological Engineering, 2016-2021E
  • Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2016
  • Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2016
  • Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2016
  • Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2016
  • Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2016
  • R&D Costs of Shanghai RAAS Blood Products, 2013-2016
  • Shanghai RAAS Blood Products' Sales from Top 5 Customers and % of Total Sales, 2013-2016
  • Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
  • Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2013-2016
  • Lot Release Volume of Blood Products of Shanghai RAAS Blood Products, 2015-2016
  • Revenue and Net Income of Shanghai RAAS Blood Products, 2016-2021E
  • Revenue and Net Income of TIANTANBIO, 2013-2016
  • Revenue Breakdown of TIANTANBIO (by Product), 2013-2016
  • Revenue Structure of TIANTANBIO (by Product), 2013-2016
  • Revenue Breakdown of TIANTANBIO (by Region), 2013-2016
  • Revenue Structure of TIANTANBIO (by Region), 2013-2016
  • Gross Margin of TIANTANBIO (by Product), 2013-2016
  • R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2016
  • Basic Situation of Major R&D Projects of TIANTANBIO by the End of 2015
  • TIANTANBIO's Sales from Top 5 Customers and % of Total Revenue, 2012-2015
  • Main Plasma Collection Stations of Chengdu Rongsheng Pharmaceuticals as of Mar 2017
  • Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2016
  • Revenue and Net Income of TIANTANBIO, 2016-2021E
  • Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2013-2016
  • Revenue Breakdown of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2016
  • Revenue Structure of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2016
  • Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2013-2016
  • Zhenxing Biopharmaceutical & Chemical's Sales from Top 5 Customers, 2013-2015
  • R&D Progress of Projects of Zhenxing Biopharmaceutical & Chemical by the End of 2015
  • R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical & Chemical, 2013-2016
  • Use of Funds Raised by Zhenxing Biopharmaceutical & Chemical through Private Issuing of A Shares, 2016
  • Distribution of Plasma Collection Stations of Guangdong Shuanglin Bio-Pharmacy as of Mar 2017
  • Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2010-2016
  • Output, Sales Volume and Inventory of Blood Products of Zhenxing Biopharmaceutical & Chemical, 2013-2015
  • Lot Release Volume of Blood Products of Zhenxing Biopharmaceutical & Chemical, 2015-2016
  • Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2016-2021E
  • Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2016
  • Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
  • Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
  • Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Product), 2015-2016
  • Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Region), 2015-2016
  • Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
  • Gross Margin of Main Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2016
  • R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2016
  • New Patents of Jiangxi Boya Bio-Pharmaceutical, 2017
  • Jiangxi Boya Bio-Pharmaceutical's Sales from Top 5 Customers, 2013-2016
  • Jiangxi Boya Bio-Pharmaceutical's Sales from Blood Products and % of Total Revenue, 2013-2016
  • Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2016
  • Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2016-2021E
  • Revenue and Net Income of Humanwell Healthcare Group, 2013-2016
  • Revenue Breakdown of Humanwell Healthcare Group (by Product), 2014-2016
  • Revenue Structure of Humanwell Healthcare Group (by Product), 2014-2016
  • Gross Margin of Humanwell Healthcare Group (by Product), 2014-2016
  • R&D Costs and % of Total Revenue of Humanwell Healthcare Group, 2013-2016
  • Humanwell Healthcare Group's Revenue from Blood Products and % of Total Revenue, 2014-2016
  • Financial Data of Wuhan Zhongyuan Ruide Biological Products, 2014-2016
  • Revenue and Net Income of Humanwell Healthcare Group, 2016-2021E
  • Development History of Sichuan Yuanda Shuyang Pharmaceutical
  • Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
  • Distribution of Plasma Stations of Sichuan Yuanda Shuyang Pharmaceutical as of Mar 2017
  • Distribution of Plasma Collection Stations of Shanghai Institute of Biological Products as of Mar 2017
  • Specification of Main Blood Products of Shanghai Institute of Biological Products
  • Main Plasma Collection Stations of Shanxi Kangbao Biological Product as of Mar 2017
  • Distribution of Plasma Collection Stations of Green Cross China as of Mar 2017
  • Specification of Main Blood Products of Green Cross China
  • Revenue and Total Profit of Walvax Biotechnology, 2013-2016
  • Financial Indicators of Hebei Da'an Pharmaceutical, 2015-2016
  • Main Plasma Collection Stations of Hebei Da'an Pharmaceutical as of Mar 2017
  • Financial Indicators of Guangdong Weilun Biological Pharmaceutical, 2016
  • Distribution of Plasma Collection Stations of Guangdong Weilun Biological Pharmaceutical as of Mar 2017
  • Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2012-2015
  • Capacity, Output and Sales Volume of Shenzhen Weiguang Biological Products (by Product), 2012-2015
  • Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (unit: RMB mln)
  • Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015
  • Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2012-2015
  • Name List and Revenue Contribution of Shenzhen Weiguang Biological Products' Top 5 Customers, 2012-2015
  • R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2012-2015
  • Shenzhen Weiguang Biological Products' Products under Research and R&D Process by the end of 2015
  • Fundraising Projects of Shenzhen Weiguang Biological Products
  • Distribution of Plasma Collection Stations of Shenzhen Weiguang Biological Products as of Mar 2017
  • Main Products of Shenzhen Weiguang Biological Products
  • Specification of Blood Products of Shenzhen Weiguang Biological Products
  • Plasma Collection Volume and Production-use Plasma Volume of Shenzhen Weiguang Biological Products, 2012-2015
  • Market Size of China Blood Product Industry, 2016-2021E
  • Merger & Acquisition Cases of Foreign Blood Product Giants
  • Merger & Acquisition Cases of China Blood Product Industry, 2008-2016
Back to Top